鼻咽癌筛查研究进展  

Research Progress on Nasopharyngeal Carcinoma Screening

作　　者：吴智聪 李彤 陈华 叶俊平 周杭宁 马征 彭一楠 曹素梅[1] WU Zhicong;LI Tong;CHEN Hua;YE Junping;ZHOU Hangning;MA Zheng;PENG Yinan;CAO Sumei(State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省鼻咽癌诊治研究重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国细胞生物学学报》2025年第3期329-335,共7页Chinese Journal of Cell Biology

摘　　要：鼻咽癌在全球的分布具有显著的地域特征,尤其高发于中国南方地区。人群筛查对高发区鼻咽癌防控具有重要意义。中国在鼻咽癌筛查领域取得了显著成就,通过对高发区人群队列的追踪研究确立了EB病毒相关标志物与鼻咽癌发病风险增加的病因学关系,为筛查策略的制定提供了依据。当前,以EB病毒双抗体(VCA/EBNA1-IgA)检测为基础的人群筛查试验已证实其可提高筛查地区人群的鼻咽癌早诊率和降低人群鼻咽癌死亡率,并具有良好的成本效益。新型鼻咽癌筛查和分流指标的出现有望进一步提高筛查的效益,实现精准筛查。该综述总结了鼻咽癌筛查的历史以及最新进展,旨在为鼻咽癌防控提供依据并推动筛查效益的提高。NPC(nasopharyngeal carcinoma)has a distinct geographical distribution worldwide,with a notably high incidence in southern China.Population-based screening is crucial for NPC prevention and control in high-incidence regions.China has achieved significant progress in NPC screening,establishing an etiological link between EBV(Epstein-Barr virus)-related biomarkers and the increased risk of NPC through longitudinal studies in high-risk cohorts.This has provided a foundation for developing effective screening strategies.Current population-based screening trials,utilizing dual antibody(VCA/EBNA1-IgA)EBV testing,have demonstrated that an increased early detection rates for NPC cases,and reduced NPC mortality in screening regions,alongside favorable cost-effectiveness.Emerging screening and triage markers offer potential to further enhance screening efficacy,moving toward precision screening.This review summarizes the history and latest advancements in NPC screening,aiming to support NPC prevention and improve screening effectiveness.

关 键 词：鼻咽癌 EB病毒 筛查 标志物 早诊率 

分 类 号：R73[医药卫生—肿瘤]